TVTX.NASDAQTravere Therapeutics, INC
Form 4: Travere Therapeutics Executive Sells Shares
Sentiment:
Insider Transaction (Form 4)
William E. Rote, Chief Research Officer of Travere Therapeutics, Inc., sold 209,048 shares of common stock on September 15, 2026.
Summary
- Option exercise/conversion: acquired 39,000 Common Stock at $25.25 ($984,750) on September 15, 2026; holds 154,745 after (Direct).
- Option exercise/conversion: acquired 39,650 Common Stock at $17.96 ($712,114) on September 15, 2026; holds 194,395 after (Direct).
- Open-market sale: disposed of 63,907 Common Stock at $61.99 ($3,961,851) on September 15, 2026; holds 130,488 after (Direct).
- Open-market sale: disposed of 29,021 Common Stock at $62.66 ($1,818,317) on September 15, 2026; holds 101,467 after (Direct).
- Open-market sale: disposed of 3,000 Common Stock at $63.65 ($190,952) on September 15, 2026; holds 98,467 after (Direct).
- Open-market sale: disposed of 270 Common Stock at $65.31 ($17,634) on September 15, 2026; holds 98,197 after (Direct).
- Option exercise/conversion: acquired 350 Common Stock at $17.96 ($6,286) on September 16, 2026; holds 98,547 after (Direct).
- Option exercise/conversion: acquired 55,000 Common Stock at $15.46 ($850,300) on September 16, 2026; holds 153,547 after (Direct).
- Option exercise/conversion: acquired 57,500 Common Stock at $26.88 ($1,545,600) on September 16, 2026; holds 211,047 after (Direct).
- Open-market sale: disposed of 65,104 Common Stock at $63.12 ($4,109,397) on September 16, 2026; holds 145,943 after (Direct).
- Open-market sale: disposed of 47,746 Common Stock at $63.61 ($3,037,247) on September 16, 2026; holds 98,197 after (Direct).
- Option exercise/conversion: disposed of 39,000 Employee stock option (right to buy) on September 15, 2026 (Direct).
- Option exercise/conversion: disposed of 39,650 Employee stock option (right to buy) on September 15, 2026; holds 350 after (Direct).
- Option exercise/conversion: disposed of 350 Employee stock option (right to buy) on September 16, 2026 (Direct).
- Option exercise/conversion: disposed of 55,000 Employee stock option (right to buy) on September 16, 2026 (Direct).
- Option exercise/conversion: disposed of 57,500 Employee stock option (right to buy) on September 16, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $13,135,397 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
William E. Rote — Officer (Chief Research Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-15 | Option exercise/conversion | Common Stock | 39,000 | $25 | $984.8K | 154,745 |
| 2026-09-15 | Option exercise/conversion | Common Stock | 39,650 | $18 | $712.1K | 194,395 |
| 2026-09-15 | Open-market sale | Common Stock | 63,907 | $62 | $4.0M | 130,488 |
| 2026-09-15 | Open-market sale | Common Stock | 29,021 | $63 | $1.8M | 101,467 |
| 2026-09-15 | Open-market sale | Common Stock | 3,000 | $64 | $191.0K | 98,467 |
| 2026-09-15 | Open-market sale | Common Stock | 270 | $65 | $17.6K | 98,197 |
| 2026-09-16 | Option exercise/conversion | Common Stock | 350 | $18 | $6.3K | 98,547 |
| 2026-09-16 | Option exercise/conversion | Common Stock | 55,000 | $15 | $850.3K | 153,547 |
| 2026-09-16 | Option exercise/conversion | Common Stock | 57,500 | $27 | $1.5M | 211,047 |
| 2026-09-16 | Open-market sale | Common Stock | 65,104 | $63 | $4.1M | 145,943 |
| 2026-09-16 | Open-market sale | Common Stock | 47,746 | $64 | $3.0M | 98,197 |
| 2026-09-15 | Option exercise/conversion | Employee stock option (right to buy) | 39,000 | — | — | 0 |
| 2026-09-15 | Option exercise/conversion | Employee stock option (right to buy) | 39,650 | — | — | 350 |
| 2026-09-16 | Option exercise/conversion | Employee stock option (right to buy) | 350 | — | — | 0 |
| 2026-09-16 | Option exercise/conversion | Employee stock option (right to buy) | 55,000 | — | — | 0 |
| 2026-09-16 | Option exercise/conversion | Employee stock option (right to buy) | 57,500 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-15 | Option exercise/conversion (39,000 shares) |
| 2026-09-15 | Option exercise/conversion (39,650 shares) |
| 2026-09-15 | Open-market sale (63,907 shares) |
| 2026-09-15 | Open-market sale (29,021 shares) |
| 2026-09-15 | Open-market sale (3,000 shares) |
| 2026-09-15 | Open-market sale (270 shares) |
| 2026-09-16 | Option exercise/conversion (350 shares) |
| 2026-09-16 | Option exercise/conversion (55,000 shares) |
| 2026-09-16 | Option exercise/conversion (57,500 shares) |
| 2026-09-16 | Open-market sale (65,104 shares) |
| 2026-09-16 | Open-market sale (47,746 shares) |
| 2026-09-15 | Option exercise/conversion (39,000 shares) |
| 2026-09-15 | Option exercise/conversion (39,650 shares) |
| 2026-09-16 | Option exercise/conversion (350 shares) |
| 2026-09-16 | Option exercise/conversion (55,000 shares) |
| 2026-09-16 | Option exercise/conversion (57,500 shares) |
Keywords
insider transaction, Form 4, TVTX, Travere Therapeutics, Inc., bearish, William E. Rote
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.